Jianbiao Zhou
- Hematology top 1%
- Acute Myeloid Leukemia Research 19
- Multiple Myeloma Research and Treatments 10
- Chronic Myeloid Leukemia Treatments 10
- Cancer Research top 2%
- MicroRNA in disease regulation 8
- Biochemistry top 1%
- Molecular Biology top 5%
- Protein Degradation and Inhibitors 13
- Ubiquitin and proteasome pathways 11
- Histone Deacetylase Inhibitors Research 10
- Protein Tyrosine Phosphatases 10
- Aging top 5%
- Co-authors
- Wee Joo ChngChien-Shing ChenSiok‐Bian NgQiang YuChonglei BiYujun ZhaoPhilip K. MooreLih‐Wen Deng
- Partner nations
- SingaporeUnited StatesChina
In The Last Decade
Jianbiao Zhou
76 papers receiving 3.5k citations
Peers
Comparison fields: 5 of 117
- Hematology 639
- Cancer Research 705
- Biochemistry 298
- Molecular Biology 2.2k
- Aging 52
Countries citing papers authored by Jianbiao Zhou
This map shows the geographic impact of Jianbiao Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianbiao Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianbiao Zhou more than expected).
Fields of papers citing papers by Jianbiao Zhou
This network shows the impact of papers produced by Jianbiao Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianbiao Zhou. The network helps show where Jianbiao Zhou may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jianbiao Zhou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 6 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 13 | |
| 6 | 2022 | 9 | |
| 7 | 2021 | 0 | |
| 8 | 2021 | 53 | |
| 9 | 2021 | 15 | |
| 10 | 2019 | 59 | |
| 11 | 2018 | 18 | |
| 12 | 2018 | 15 | |
| 13 | 2017 | 12 | |
| 14 | 2017 | 18 | |
| 15 | 2016 | 30 | |
| 16 | Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: from molecular pathogenesis to therapeutic target | 2015 | 1 |
| 17 | 2014 | 28 | |
| 18 | 2012 | 30 | |
| 19 | 2009 | 52 | |
| 20 | 2004 | 34 |
About Jianbiao Zhou
Jianbiao Zhou is a scholar working on Hematology, Cancer Research and Molecular Biology, having authored 81 papers that have together received 3.5k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (19 papers), Protein Degradation and Inhibitors (13 papers), Ubiquitin and proteasome pathways (11 papers), Multiple Myeloma Research and Treatments (10 papers), Histone Deacetylase Inhibitors Research (10 papers), Protein Tyrosine Phosphatases (10 papers), Chronic Myeloid Leukemia Treatments (10 papers) and MicroRNA in disease regulation (8 papers). The work is most often cited by research in Hematology (639 citations), Cancer Research (705 citations) and Biochemistry (298 citations). Jianbiao Zhou has collaborated with scholars based in Singapore, United States and China. Frequent co-authors include Wee Joo Chng, Chien-Shing Chen, Siok‐Bian Ng, Qiang Yu, Chonglei Bi, Yujun Zhao, Philip K. Moore, Lih‐Wen Deng, Choon‐Hong Tan and Ling Li. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.